Confirmed Diagnosis of ß-thalassemia Major

Hematology

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.

$3.6B marketMature→ Stable30 products15 companies

Key Trends

IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders

Career Verdict

Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	IMBRUVICA (ibrutinib)	AbbVie	$2.4B	65%	Peak	Stable	9.0yr
2	PROMACTA (eltrombopag olamine)	Novartis	$558M	15%	LOE Approaching	Declining	1.7yr
3	AURYXIA (ferric citrate)	Ipsen	$183M	5%	Peak	Stable	4.2yr
4	OXBRYTA (voxelotor)	Pfizer	$101M	3%	Peak	Growing	11.4yr
5	DOPTELET (avatrombopag maleate)	Unknown	$96M	3%	LOE Approaching	Declining	1.2yr

#1IMBRUVICA

$2.4B

AbbVie·Peak9.0yr

#2PROMACTA

$558M

Novartis·LOE Approaching1.7yr

#3AURYXIA

$183M

Ipsen·Peak4.2yr

#4OXBRYTA

$101M

Pfizer·Peak11.4yr

#5DOPTELET

$96M

Unknown·LOE Approaching1.2yr

Drug Class Breakdown

Protein Kinase Inhibitors

$2.4B(65%)

dominates market, stable

TPO-receptor agonists

$654M(18%)

multiple players, patent risk

Iron metabolism modulators

$183M(5%)

niche, CKD-focused

Hemoglobin polymerization inhibitors

$101M(3%)

sickle cell focused, growing

JAK2 inhibitors

$50M(1%)

myeloproliferative neoplasms, early growth

Erythropoiesis-stimulating agents

$60M(2%)

legacy class, biosimilar pressure

Leukocyte growth factors

$68M(2%)

biosimilar-saturated, mature

Career Outlook

Stable

Hematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.

Breaking In

Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.

For Experienced Professionals

Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).

In-Demand Skills

Managed care/payer strategyHematologic malignancy genetics (BTK, JAK2 mutations)TPO-receptor pharmacologyRare disease diagnosis and patient identificationBiosimilar/generic competitive strategyMedical writing for limited indication populations

Best For

Medical Science Liaison (rare disease focus)Brand Manager (specialty hematology)Managed Care DirectorClinical Operations ManagerPayer Strategy AnalystHealth Economics & Outcomes Research (HEOR) specialist

Hiring Landscape

$91K-$204K

Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.

102

Open Roles

Companies Hiring

Departments

Top Hiring Companies

By Department

Commercial(24%)

$201K

Clinical Operations(18%)

$91K

Medical Affairs(15%)

$204K

Manufacturing(7%)

$175K

R&D(7%)

$147K

Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

San Rocco TherapeuticsFL - Tampa

1 program

Autologous CD34+ cells transduced with TNS9.3.55Phase 11 trial

Active Trials

NCT01639690Active Not Recruiting10Est. Jul 2027

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

San Rocco TherapeuticsAutologous CD34+ cells transduced with TNS9.3.55

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

NCT01639690 San Rocco TherapeuticsAutologous CD34+ cells transduced with TNS9.3.55

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

Start: Jul 2012Est. completion: Jul 202710 patients

Phase 1Active Not Recruiting

Related Jobs in Hematology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Anemia(259)Myelofibrosis(78)Aplastic Anemia(40)Polycythemia Vera(40)Primary Myelofibrosis(31)Thrombocytopenia(31)Iron Deficiency Anemia(26)Immune Thrombocytopenia(26)Primary Immune Thrombocytopenia(24)Beta-Thalassemia(23)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.